Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.34 USD
+0.01 (0.75%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Earnings News For AKBA
-
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
-
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
-
Akebia Therapeutics: Q3 Earnings Snapshot
-
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
-
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
-
Akebia Therapeutics: Q2 Earnings Snapshot
-
Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
-
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
-
Akebia Therapeutics: Q1 Earnings Snapshot
-
Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
-
Will Akebia Therapeutics (AKBA) Report Negative Q1 Earnings? What You Should Know
-
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
-
Akebia Therapeutics: Q4 Earnings Snapshot
-
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
-
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
-
Akebia Therapeutics: Q3 Earnings Snapshot
-
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
-
Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates
-
Akebia Therapeutics: Q2 Earnings Snapshot
-
Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
-
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
-
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
-
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
-
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates